Glaukos' Epioxa Shows Durable Keratoconus Results in 3-Year Study

  • Glaukos' Epioxa® demonstrated sustained 1.9 diopter improvement in corneal curvature over three years.
  • 29% of treated eyes gained two or more lines of best-corrected visual acuity at year 3.
  • No serious adverse events reported, with 92% of study eyes completing the three-year follow-up.
  • Epioxa offers an incision-free, epithelium-on cross-linking treatment for keratoconus.

Glaukos' positive three-year data for Epioxa reinforces its potential as a transformative treatment for keratoconus, a condition often underdiagnosed and undertreated. The durable efficacy and safety profile could expand the company's footprint in corneal disorders, complementing its existing portfolio in glaucoma and retinal therapies. The results position Epioxa as a key differentiator in a market increasingly focused on minimally invasive, long-lasting solutions.

Regulatory Approval
Whether Glaukos can secure broader regulatory approvals for Epioxa beyond current indications.
Commercialization Pace
The pace at which Epioxa gains market adoption among ophthalmologists treating keratoconus.
Competitive Positioning
How Epioxa's long-term data will position it against existing and emerging keratoconus treatments.